http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 21:18:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+17++Filed+by%3A+Karydas+Daphne/26661629.html si-local-file:///var/storage/secattach/20260617/26661629.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+17++Filed+by%3A+Karydas+Daphne/26661629.html Wed, 17 Jun 2026 21:18:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+17++Filed+by%3A+Karydas+Daphne/26661629.html si-local-file:///var/storage/secattach/20260617/26661629.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+17++Filed+by%3A+Karydas+Daphne/26661629.html Wed, 17 Jun 2026 21:18:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+15++Filed+by%3A+Rodman+David+Malcom/26661630.html si-local-file:///var/storage/secattach/20260617/26661630.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+15++Filed+by%3A+Rodman+David+Malcom/26661630.html Wed, 17 Jun 2026 21:18:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+15++Filed+by%3A+Rodman+David+Malcom/26661630.html si-local-file:///var/storage/secattach/20260617/26661630.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+15++Filed+by%3A+Rodman+David+Malcom/26661630.html Wed, 17 Jun 2026 21:18:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26660199.html si-local-file:///var/storage/secattach/20260617/26660199.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26660199.html Wed, 17 Jun 2026 16:20:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26660199.html si-local-file:///var/storage/secattach/20260617/26660199.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26660199.html Wed, 17 Jun 2026 16:20:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Karydas+Daphne/26660128.html si-local-file:///var/storage/secattach/20260617/26660128.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Karydas+Daphne/26660128.html Wed, 17 Jun 2026 16:16:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Karydas+Daphne/26660128.html si-local-file:///var/storage/secattach/20260617/26660128.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Karydas+Daphne/26660128.html Wed, 17 Jun 2026 16:16:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26648288.html si-local-file:///var/storage/secattach/20260615/26648288.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26648288.html Mon, 15 Jun 2026 16:58:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26648288.html si-local-file:///var/storage/secattach/20260615/26648288.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26648288.html Mon, 15 Jun 2026 16:58:00 -0400 MLYS O.50481249 http://www.streetinsider.com/Corporate+News/Mineralys+presents+heart+failure+biomarker+data+for+lorundrostat+at+ENDO+2026/26642925.html <p>Mineralys Therapeutics Inc (NASDAQ: MLYS) presented data showing its investigational drug lorundrostat was associated with reductions in heart failure risk biomarkers in patients with uncontrolled hypertension.</p><p>The company presented the findings in a late-breaking poster at the Endocrine Society's annual meeting ENDO 2026 in Chicago. The analysis examined circulating protein biomarkers from 1,004 participants in the company's Launch-HTN and Advance-HTN trials after 12 weeks of treatment.</p><p>According to the data, lorundrostat showed significant reductions in 6 of 11 candidate causal risk biomarkers of incident heart failure, including NT-proBNP. The treatment also led to coordinated changes in key biomarkers, with reductions in markers http://www.streetinsider.com/Corporate+News/Mineralys+presents+heart+failure+biomarker+data+for+lorundrostat+at+ENDO+2026/26642925.html Sun, 14 Jun 2026 14:01:03 -0400 MLYS http://www.streetinsider.com/FDA/Mineralys+presents+heart+failure+biomarker+data+for+lorundrostat+at+ENDO+2026/26642925.html <p>Mineralys Therapeutics Inc (NASDAQ: MLYS) presented data showing its investigational drug lorundrostat was associated with reductions in heart failure risk biomarkers in patients with uncontrolled hypertension.</p><p>The company presented the findings in a late-breaking poster at the Endocrine Society's annual meeting ENDO 2026 in Chicago. The analysis examined circulating protein biomarkers from 1,004 participants in the company's Launch-HTN and Advance-HTN trials after 12 weeks of treatment.</p><p>According to the data, lorundrostat showed significant reductions in 6 of 11 candidate causal risk biomarkers of incident heart failure, including NT-proBNP. The treatment also led to coordinated changes in key biomarkers, with reductions in markers http://www.streetinsider.com/FDA/Mineralys+presents+heart+failure+biomarker+data+for+lorundrostat+at+ENDO+2026/26642925.html Sun, 14 Jun 2026 14:01:03 -0400 MLYS http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html <p align="center"><em>– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –</em></p> <p align="center"><em>– Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure –</em></p> <p align="justify">RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Presents+Late-Breaking+Data+on+Lorundrostat+and+Heart+Failure+Risk+Biomarkers+at+The+Endocrine+Society+Annual+Meeting+%28ENDO+2026%29/26642909.html Sun, 14 Jun 2026 10:00:00 -0400 A.06822034 A.50203974 MLYS O.00028300 O.20026344 O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+10++Filed+by%3A+Rodman+David+Malcom/26642371.html si-local-file:///var/storage/secattach/20260612/26642371.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Jun+10++Filed+by%3A+Rodman+David+Malcom/26642371.html Fri, 12 Jun 2026 18:05:00 -0400 MLYS O.50481249